<DOC>
	<DOCNO>NCT00556192</DOCNO>
	<brief_summary>This prospective randomize control trial undertaken evaluate safety efficacy anti-CD20 monoclonal antibody , rituximab , use 1. monotherapy , 2. combination cyclophosphamide , treatment proliferative lupus nephritis , compare standard immunosuppressive therapy cyclophosphamide azathioprine .</brief_summary>
	<brief_title>Can Targeted Elimination B-cell Depletion Therapy and/or Combination Therapy Systemic Lupus Erythematosus</brief_title>
	<detailed_description>Twenty patient randomize 3 treatment arm receive : - Rituximab 1000 mg give 2 week apart . On day rituximab , 'pulse ' methylprednisolone 250mg IV give follow prednisolone 30mg/day Day 2 Day 5 . - A treatment dose rituximab 1000mg give 2 week apart 'pulse ' methylprednisolone 250mg IV give follow prednisolone 30mg/day Day 2 Day 5 , 'pulse ' cyclophosphamide 500mg/m2 baseline day 14 . - Sequential therapy oral cyclophosphamide ( 50 100 mg/day ) 6 month follow azathioprine ( 2.5mg/kg/day ) maintenance 12 month . Oral prednisolone give 0.5 mg/kg/day ( 30 mg daily ) 4 week , taper 5 mg every 2 week thereafter 5mg /day rest study period . All patient would start angiotensin convert enzyme inhibitor commencement trial continue dosage throughout study period . Patients antimalarial agent statins baseline allow continue . Clinical examination laboratory investigation perform 0 , 4 , 8 , 12 , 24 , 36 48 week time treatment . At visit , patient evaluate clinical manifestation SLE side effect therapy . Laboratory parameter measure include complete blood cell count differential platelet count , chemistry survey , urinalysis , 24- hour urinary protein excretion creatinine clearance .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Age &gt; 18 year Active proliferative lupus nephrite Biopsy confirm active proliferative lupus nephritis within 3 month prior enrollment Proteinuria &gt; = 2g/day Active urinary sediment Activity index &gt; = 6 Elevated antidoublestranded ( antidsDNA ) level baseline Agreement practice birth control SLE accord American College Rheumatology Criteria Informed consent obtain Preexisting renal failure History cancer Human immunodeficiency virus infection Active hepatitis B C infection Active tuberculosis Diabetes mellitus A ny chronic disease Unwillingness comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>SLE</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Methylprednisolone</keyword>
	<keyword>Cyclophosphamide</keyword>
</DOC>